Long noncoding RNA (lncRNA)
IDH1
antisense RNA 1 (
IDH1-AS1
) is involved in the progression of multiple cancers, but its role in epithelial ovarian cancer (EOC) is unknown. Therefore, we investigated the expression levels of
IDH1-AS1
in EOC cells and normal ovarian epithelial cells by quantitative real-time PCR (qPCR). We first evaluated the effects of
IDH1-AS1
on the proliferation, migration, and invasion of EOC cells through cell counting kit-8, colony formation, EdU, transwell, wound-healing, and xenograft assays. We then explored the downstream targets of
IDH1-AS1
and verified the results by a dual-luciferase reporter, qPCR, rescue experiments, and Western blotting. We found that the expression levels of
IDH1-AS1
were lower in EOC cells than in normal ovarian epithelial cells. High
IDH1-AS1
expression of EOC patients from the Gene Expression Profiling Interactive Analysis database indicated a favorable prognosis, because
IDH1-AS1
inhibited cell proliferation and xenograft tumor growth of EOC.
IDH1-AS1
sponged miR-518c-5p whose overexpression promoted EOC cell proliferation. The miR-518c-5p mimic also reversed the proliferation-inhibiting effect induced by
IDH1-AS1
overexpression. Furthermore, we found that RNA binding motif protein 47 (RBM47) was the downstream target of miR-518c-5p, that upregulation of RBM47 inhibited EOC cell proliferation, and that RBM47 overexpressing plasmid counteracted the proliferation-promoting effect caused by the
IDH1-AS1
knockdown. Taken together,
IDH1-AS1
may suppress EOC cell proliferation and tumor growth
via
the miR-518c-5p/RBM47 axis.